A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap

The objective of this study is to compare the safety and efficacy of masitinib (AB1010) to placebo in patients with mastocytosis with handicap.

Smouldering Systemic Mastocytosis ,Indolent systemic mastocytosis ,Cutaneous Mastocytosis With Handicap ,mastocytosis

Kusajili – Clinical trials directory